ATE146970T1 - Behandlung von entzündungen - Google Patents

Behandlung von entzündungen

Info

Publication number
ATE146970T1
ATE146970T1 AT91920172T AT91920172T ATE146970T1 AT E146970 T1 ATE146970 T1 AT E146970T1 AT 91920172 T AT91920172 T AT 91920172T AT 91920172 T AT91920172 T AT 91920172T AT E146970 T1 ATE146970 T1 AT E146970T1
Authority
AT
Austria
Prior art keywords
treatment
inflammation
cells
mast
mediators
Prior art date
Application number
AT91920172T
Other languages
English (en)
Inventor
John Lezdey
Allan Wachter
Original Assignee
John Lezdey
Allan Wachter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27416749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE146970(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/683,620 external-priority patent/US5190917A/en
Application filed by John Lezdey, Allan Wachter filed Critical John Lezdey
Application granted granted Critical
Publication of ATE146970T1 publication Critical patent/ATE146970T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91920172T 1990-10-16 1991-09-26 Behandlung von entzündungen ATE146970T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59824190A 1990-10-16 1990-10-16
US64372791A 1991-01-18 1991-01-18
US07/683,620 US5190917A (en) 1986-12-24 1991-04-11 Treatment of psoriasis

Publications (1)

Publication Number Publication Date
ATE146970T1 true ATE146970T1 (de) 1997-01-15

Family

ID=27416749

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91920172T ATE146970T1 (de) 1990-10-16 1991-09-26 Behandlung von entzündungen

Country Status (10)

Country Link
EP (1) EP0512090B2 (de)
AT (1) ATE146970T1 (de)
AU (1) AU679165B2 (de)
CA (1) CA2091354C (de)
DE (1) DE69123960T2 (de)
DK (1) DK0512090T4 (de)
ES (1) ES2096665T3 (de)
GR (1) GR3022533T3 (de)
OA (1) OA09768A (de)
WO (1) WO1992006706A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4244735A1 (de) * 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
US5614198A (en) * 1995-07-25 1997-03-25 The Trustees Of The University Of Pennsylvania Bowman-Birk Inhibitor compositions for treatment of inflammatory disease
DE19600480A1 (de) * 1996-01-09 1997-07-10 Beiersdorf Ag Verwendung von Serin-Proteinasen gegen Akne und entzündete Comedonen
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
EP0834556A1 (de) * 1996-09-25 1998-04-08 Academisch Ziekenhuis Leiden Verfahren zur Zellkultivierung
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
WO1999049887A1 (en) * 1998-04-01 1999-10-07 Biotech Australia Pty. Limited Use of protease inhibitors for treating skin wounds
EP1163900A1 (de) * 1998-11-05 2001-12-19 Protease Sciences, Incorporated Kosmetische Zubereitung human-typische Serin-Protease-Inhibitoren enthaltend
WO2000044390A1 (en) * 1999-02-01 2000-08-03 John Lezdey Treatment of bladder and gastrointestinal mastocytosis
CA2362565A1 (en) * 1999-02-22 2000-08-31 Eric F. Bernstein Compositions and methods for prevention of photoaging
EP1234581B1 (de) 1999-10-26 2005-12-28 Japan Tissue Engineering Co., Ltd. Verwendung des sekretorischen leukozytären Proteasehemmers für Keloide und Narben
WO2001030379A2 (en) 1999-10-27 2001-05-03 Alexandra Lucas Compositions and methods for preventing and treating transplant rejection
WO2001064031A2 (en) * 2000-03-01 2001-09-07 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Slpi knockout mice and methods for wound treatment
EP1365798B1 (de) 2000-09-29 2009-12-30 Viron Therapeutics, Inc. Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
CA2446197C (en) * 2001-04-30 2011-12-13 Switch Biotech Ag Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, or of a cell which is expressing an act polypeptide, or a nucleic acid encoding it, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds and for identifying pharmacologically active substances
WO2002087511A2 (en) * 2001-05-02 2002-11-07 Center For Blood Research, Inc. Modulators of elastase inhibitor secretion
GB0125594D0 (en) * 2001-10-25 2001-12-19 Univ Sheffield Inhibitors for inactivating allergens
EP1415664A1 (de) * 2002-10-30 2004-05-06 Switch Biotech Aktiengesellschaft Verwendung von Alpha-1-antichymotrypsin in Kombination mit Alpha-1-antitrypsin zur Behandlung/Vorbeugung von schlecht heilenden arteriellen oder diabetischen Wunden
JP2006508971A (ja) * 2002-11-20 2006-03-16 アライバ−プロメティック インコーポレイティド プロテアーゼ阻害剤を使用して炎症性疾患を治療する組成物及び方法
CA2536918A1 (en) 2003-08-26 2005-03-03 Leland Shapiro Compositions of, and methods for, alpha-1 antitrypsin fc fusion molecules
US7226995B2 (en) 2003-10-23 2007-06-05 Stc.Unm Use of C-reactive protein to treat immune complex-mediated renal disease
GB0411145D0 (en) * 2004-05-19 2004-06-23 Imp College Innovations Ltd Protease inhibitors and their therapeutic applications
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
WO2008060362A2 (en) * 2006-09-27 2008-05-22 The Regents Of The University Of California Methods and compositions for the treatment of skin diseases and disorders
WO2012029061A2 (en) 2010-08-31 2012-03-08 Uri Wormser POLYPEPTIDES DERIVED FROM α-1 ANTITRYPSIN AND METHODS OF USE THEREOF
US9518107B2 (en) 2010-08-31 2016-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Pharmaceutical compositions containing polypeptides derived from α-1 antitrypsin and methods of use thereof
KR102103476B1 (ko) 2011-06-24 2020-04-23 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
KR20140137347A (ko) 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
BR112014027333A2 (pt) * 2012-05-01 2017-07-18 Univ Duke composição, métodos de tratamento ou melhora, de prevenção, e, de diagnóstico de uma condição prejudicial que está associada com o teor elevado de sulfato de heparano em um indivíduo que foi o receptor de um órgão, tecido ou células transplantados
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
WO2014159771A1 (en) 2013-03-13 2014-10-02 The Regents Of The University Of California Prevention of rosacea inflammation
CA3030165A1 (en) * 2016-07-19 2018-01-25 Arete Discoveries, Inc. Biomarkers for detection and treatment of mast cell activity-associated disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304971B1 (de) † 1982-08-13 1998-02-04 ZymoGenetics, Inc. Verfahren zur Herstellung eines Polypeptids mit der Proteasehemmenden Aktivität von Säugetier-alpha-1-Antitrypsin
AU3145184A (en) * 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4916117A (en) * 1986-12-24 1990-04-10 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5114917A (en) † 1986-12-24 1992-05-19 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5008242A (en) * 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
JP2656944B2 (ja) † 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化

Also Published As

Publication number Publication date
DE69123960T2 (de) 1997-05-07
DK0512090T4 (da) 2007-01-15
EP0512090B2 (de) 2006-11-22
AU8929091A (en) 1992-05-20
AU679165B2 (en) 1997-06-26
CA2091354A1 (en) 1992-04-17
ES2096665T3 (es) 1997-03-16
DK0512090T3 (da) 1997-06-16
EP0512090A1 (de) 1992-11-11
EP0512090A4 (en) 1993-05-05
EP0512090B1 (de) 1997-01-02
GR3022533T3 (en) 1997-05-31
DE69123960D1 (de) 1997-02-13
WO1992006706A1 (en) 1992-04-30
CA2091354C (en) 2005-04-12
OA09768A (en) 1993-11-30

Similar Documents

Publication Publication Date Title
DE69123960D1 (de) Behandlung von entzündungen
ES2078570T3 (es) Derivados de n-acil-alfa-aminoacidos.
EA200101166A1 (ru) Ингибиторы металлопротеаз
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
DK0380367T3 (da) Præparater og fremgangsmåde til sygdomsbehandling
ATE207355T1 (de) Behandlung von hyperproliferativen gefässerkrankungen
PT92821A (pt) Processo para a preparacao composicoes farmaceuticas para o combate de doencas do tipo psoriase, bem como doencas inflamatorias, incorporando azelastina como substancia activa
MX9204703A (es) Acidos n-acil-n-heterociclilalquilamino, proceso para su obtencion y composicion farmaceutica que los contiene.
DK0432117T3 (da) Farmaceutisk præparat til behandling af inflammation
DE68902798D1 (de) Verwendung von polymeren bei einer behandlung.
ES2058125T3 (es) Derivados de piperidina para el tratamiento del dolor.
ES2118708T3 (es) Composiciones de piperidina y su preparacion y utilizacion.
ES2102097T3 (es) Acidos fenilalcan(quen)oicos con actividad antagonista del leucotrieno b4.
ATE81004T1 (de) Laktamimide in der behandlung arzneiresistenter protozoeninjektionen.
ES2032922T3 (es) Empleo de los paf-aceter antagonicos para la fabricacion de un medicamento y procedimiento para determinar la eficacia de los mismos.
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
DE69108748D1 (de) Antithrombin-Lösung und ihre Verwendung.
ES8801173A1 (es) Procedimiento de producir agentes terapeuticos y profilacticos para ulceras pepticas
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
ES2064983T3 (es) Dispositivo para el tratamiento termico y/o humectacion de carretes, canillas y conos.
ES2166838T3 (es) 6-(triazolil(3-(trifluorometil)fenil)metil)-2-quinolinonas y -quinolinationas.
ES2036533T3 (es) Derivados de 1,6-naftiridina, procedimientos para su obtencion y de medicamentos que los contienen para el tratamiento de enfermedades de los vasos sanguineos.
SE8902607D0 (sv) Oxaza heterocycles and pharmaceutical compositions containing same
ITMI920979A1 (it) N-acil derivati di aminoalcooli come agenti terapeutici attivi sull'edema neurogenico endoneurale a livello del nervo periferico.
DE69018099D1 (de) Polyamin-Derivate als antineoplastische Mittel.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties